Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD8055||AZD-8055||mTOR Inhibitor 51 PI3K Inhibitor (Pan) 37||AZD8055 is a PI3K/MTOR inhibitor that reduces downstream signaling, resulting in decreased tumor cell growth (PMID: 20028854, PMID: 31519159).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 act mut STK11 loss||breast cancer||sensitive||AZD8055||Preclinical||Actionable||In a preclinical study, AZD8055 inhibited tumor growth in a mouse model of spontaneous breast cancer harboring an ERBB2 (HER2) activating mutation and loss of STK11 (LKB1), which was enhanced by the addition of 2-DG (2-deoxyglucose) (PMID: 25436981).||25436981|
|Unknown unknown||Advanced Solid Tumor||not applicable||AZD8055||Phase I||Actionable||In a Phase I trial, AZD8055 treatment demonstrated safety and tolerability, and resulted in stable disease for more than 4 months in 14% (7/49) of patients with advanced solid tumors or lymphoma (PMID: 22935583).||22935583|
|ARID1A loss||Her2-receptor positive breast cancer||resistant||AZD8055||Preclinical - Cell culture||Actionable||In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to AZD8055 in culture (PMID: 27172896).||27172896|
|PIK3CA amp||head and neck squamous cell carcinoma||predicted - sensitive||AZD8055||Preclinical - Cell culture||Actionable||In a preclinical study, treatment with AZD8055 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PIK3CA amplification in culture (PMID: 28446642).||28446642|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|